A phaseI/IIa clinical study of cetuximab combined with fruquintinib in the third-line treatment of RAS/BRAF wild-type colorectal cancer.

Yong Li,Yan-chun Qu,Yufeng Liu,Yi-Hong Liu,Yan-juan Zhu,Yongsong Ye,Xian Chen,Xin Qu,Li-rong Liu,Wenzhu Li,Fangfang Hou,Hai Bo Zhang

A phaseI/IIa clinical study of cetuximab combined with fruquintinib in the third-line treatment of RAS/BRAF wild-type colorectal cancer.

2021

Yong Li
Yan-chun Qu
Yufeng Liu
Yi-Hong Liu
Yan-juan Zhu
Yongsong Ye
Xian Chen
Xin Qu
Li-rong Liu
Wenzhu Li
Fangfang Hou
Hai Bo Zhang

TPS151Background: The standard third-line treatment of mCRC is regofenib, fruquintinib or TAS-102. However, the efficacy was not satisfied. Because VEGF and EGFR share the downstream signal pathway...

Keywords:

Wild type
Medicine
Fruquintinib
Colorectal cancer
Cancer research
VEGF receptors
Cetuximab
signal pathway
Third line treatment
clinical study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations